Under the agreement, WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary WuXiTecan-2 ...
WuXi XDC inks collaboration with Earendil Labs on WuXiTecan-2 payload-linker technology platform: Shanghai, China Monday, March 2, 2026, 17:00 Hrs [IST] WuXi XDC Cayman Inc. (WuXi ...
Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ('WuXi XDC', stock ...
WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary technology for use against multiple specific targets.
[Reference] Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQᵀᴹ technology (Press ...
WuXi XDC Cayman Inc. has entered a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform.
SUZHOU, China, Feb. 9, 2026 /PRNewswire/ -- BioDlink announced that it has received a formal letter of appreciation from its client, Chengdu Kanghong Pharmaceutical Group ("Kanghong Pharmaceutical"), ...
US biotech Earendil Labs has entered a strategic collaboration with Hong Kong-listed WuXi XDC (HKEX: 2268), securing an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results